AVROBIO Inc
NASDAQ:TECX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AVROBIO Inc
Pre-Tax Income
AVROBIO Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AVROBIO Inc
NASDAQ:TECX
|
Pre-Tax Income
-$72.9m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
0%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$9.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
42%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$5.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
16%
|
|
AVROBIO Inc
Glance View
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.
See Also
What is AVROBIO Inc's Pre-Tax Income?
Pre-Tax Income
-72.9m
USD
Based on the financial report for Dec 31, 2025, AVROBIO Inc's Pre-Tax Income amounts to -72.9m USD.
What is AVROBIO Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
-31%
Over the last year, the Pre-Tax Income growth was -26%. The average annual Pre-Tax Income growth rates for AVROBIO Inc have been -31% over the past three years .
